Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK)
HKD 1.39
(-0.71%)
HKD 1.39
(-0.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 226.38 Million CNY | -1.27% |
| 2022 | 231.42 Million CNY | 12.36% |
| 2021 | 206.49 Million CNY | 20.77% |
| 2020 | 172.91 Million CNY | -7.0% |
| 2019 | 196.73 Million CNY | 1.79% |
| 2018 | 206.16 Million CNY | -4.2% |
| 2017 | 194.09 Million CNY | 0.02% |
| 2016 | 186.82 Million CNY | 17.18% |
| 2015 | 156.53 Million CNY | -7.45% |
| 2014 | 175.71 Million CNY | 54.2% |
| 2013 | 108.94 Million CNY | 38.17% |
| 2012 | 78.7 Million CNY | 8.93% |
| 2011 | 71.9 Million CNY | 26.61% |
| 2010 | 56.79 Million CNY | 55.25% |
| 2009 | 36.58 Million CNY | -5.87% |
| 2008 | 38.86 Million CNY | 28.14% |
| 2007 | 30.33 Million CNY | 95.12% |
| 2006 | 15.54 Million CNY | -28.26% |
| 2005 | 21.66 Million CNY | 68.24% |
| 2004 | 12.87 Million CNY | 24.03% |
| 2003 | 10.38 Million CNY | -37.62% |
| 2002 | 16.64 Million CNY | -57.72% |
| 2001 | 39.37 Million CNY | -16.78% |
| 2000 | 47.31 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 70.51 Million CNY | 0.0% |
| 2024 Q1 | 70.51 Million CNY | 112.75% |
| 2023 Q3 | 58.54 Million CNY | 46.69% |
| 2023 Q1 | 67.22 Million CNY | -9.03% |
| 2023 Q2 | 39.91 Million CNY | -40.63% |
| 2023 FY | - CNY | -1.27% |
| 2023 Q4 | 33.14 Million CNY | -43.39% |
| 2022 FY | - CNY | 12.36% |
| 2022 Q3 | 31.88 Million CNY | -38.89% |
| 2022 Q4 | 73.89 Million CNY | 131.74% |
| 2022 Q1 | 39.86 Million CNY | -32.32% |
| 2022 Q2 | 52.18 Million CNY | 30.9% |
| 2021 Q1 | 23.72 Million CNY | -54.43% |
| 2021 Q3 | 56.02 Million CNY | 43.77% |
| 2021 FY | - CNY | 20.77% |
| 2021 Q4 | 58.89 Million CNY | 5.12% |
| 2021 Q2 | 38.96 Million CNY | 64.25% |
| 2020 Q1 | 16.96 Million CNY | -76.33% |
| 2020 Q2 | 44.88 Million CNY | 164.56% |
| 2020 Q3 | 36.84 Million CNY | -17.9% |
| 2020 Q4 | 52.06 Million CNY | 41.31% |
| 2020 FY | - CNY | -7.0% |
| 2019 FY | - CNY | 1.79% |
| 2019 Q4 | 71.65 Million CNY | 75.76% |
| 2019 Q3 | 40.77 Million CNY | -9.25% |
| 2019 Q1 | 18.05 Million CNY | -76.85% |
| 2019 Q2 | 44.92 Million CNY | 148.77% |
| 2018 FY | - CNY | -4.2% |
| 2018 Q3 | 42.87 Million CNY | -0.7% |
| 2018 Q4 | 78.01 Million CNY | 81.96% |
| 2018 Q2 | 43.17 Million CNY | 93.51% |
| 2018 Q1 | 22.31 Million CNY | -65.48% |
| 2017 Q2 | 44.18 Million CNY | 108.98% |
| 2017 Q3 | 42.8 Million CNY | -3.12% |
| 2017 FY | - CNY | 0.02% |
| 2017 Q4 | 64.64 Million CNY | 51.02% |
| 2017 Q1 | 21.14 Million CNY | -66.68% |
| 2016 FY | - CNY | 17.18% |
| 2016 Q4 | 63.45 Million CNY | 52.41% |
| 2016 Q3 | 41.63 Million CNY | -1.74% |
| 2016 Q2 | 42.37 Million CNY | 112.57% |
| 2016 Q1 | 19.93 Million CNY | -53.74% |
| 2015 FY | - CNY | -7.45% |
| 2015 Q1 | 17.39 Million CNY | -75.56% |
| 2015 Q2 | 46.77 Million CNY | 168.97% |
| 2015 Q3 | 30.73 Million CNY | -34.29% |
| 2015 Q4 | 43.08 Million CNY | 40.16% |
| 2014 Q2 | 43.97 Million CNY | 202.9% |
| 2014 FY | - CNY | 54.2% |
| 2014 Q4 | 71.17 Million CNY | 134.92% |
| 2014 Q3 | 30.29 Million CNY | -31.11% |
| 2014 Q1 | 14.51 Million CNY | -27.5% |
| 2013 Q3 | 24.03 Million CNY | -37.77% |
| 2013 FY | - CNY | 38.17% |
| 2013 Q1 | 12.58 Million CNY | -11.77% |
| 2013 Q2 | 38.62 Million CNY | 206.92% |
| 2013 Q4 | 20.02 Million CNY | -16.68% |
| 2012 Q4 | 14.26 Million CNY | -11.5% |
| 2012 Q2 | 38.78 Million CNY | 268.62% |
| 2012 FY | - CNY | 8.93% |
| 2012 Q1 | 10.52 Million CNY | -31.8% |
| 2012 Q3 | 16.11 Million CNY | -58.45% |
| 2011 Q1 | 16.34 Million CNY | 54.41% |
| 2011 Q2 | 18.94 Million CNY | 15.92% |
| 2011 Q3 | 11.14 Million CNY | -41.17% |
| 2011 Q4 | 15.42 Million CNY | 38.45% |
| 2011 FY | - CNY | 26.61% |
| 2010 Q1 | 10.5 Million CNY | 0.0% |
| 2010 FY | - CNY | 55.25% |
| 2010 Q3 | 8.27 Million CNY | -41.35% |
| 2010 Q4 | 10.58 Million CNY | 27.94% |
| 2010 Q2 | 14.1 Million CNY | 34.31% |
| 2009 FY | - CNY | -5.87% |
| 2009 Q2 | 7.24 Million CNY | 0.0% |
| 2008 FY | - CNY | 28.14% |
| 2007 FY | - CNY | 95.12% |
| 2006 FY | - CNY | -28.26% |
| 2005 FY | - CNY | 68.24% |
| 2004 FY | - CNY | 24.03% |
| 2003 FY | - CNY | -37.62% |
| 2002 FY | - CNY | -57.72% |
| 2001 FY | - CNY | -16.78% |
| 2000 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -50.525% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 92.369% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 274.791% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -98.939% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 550.714% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -106.146% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 45.889% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -195.42% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 965.104% |
| SSY Group Limited | 2.11 Billion HKD | 89.294% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -10.763% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 47.342% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 98.533% |